CLIX Flashcards

1
Q

Be familiar with the components of an Arterial Blood Gas: pH, pCO2, pO2, HCO3-, Base Excess, Anion Gap, p50, and the underlying physiology and anatomy for a normal result.

A

Units Reference range
pH 7.35 -7.45
pCO2 mmHg 35 - 45
pO2 mmHg 83 - 108
Oxygen saturation % 94 – 98
Bicarbonate mmol/L 18 – 26*
p50 mmHg 24 – 28
Base Excess mmol/L -2.0 to +3.0
Anion Gap: = (Na+) − (HCO3¯+ Cl¯)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Be able to interpret an Arterial Blood Gas analysis and to be able to distinguish between
metabolic and respiratory acidosis and alkalosis.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Correctly apply the compensation rules to identify a mixed acid-base disturbance

A

Metabolic acidosis: Winter’s formula: Expected level of pCO2 = 1.5 x bicarbonate level + 8 ±2 mmHg

Metabolic alkalosis: For every 1mmol/L↑ in HCO3─ above 24.4 mmol/L, pCO2↑above 40 mmHgby
0.6 - 0.75 mmHg, OR
Expected level of pCO2 = 0.7 x bicarbonate level + 20 ±5 mmHg

Respiratory acidosis: For every 10mmHg↑in pCO2 above 40 mmHg, HCO3 ─ ↑ above 24.4 mmol/L by
1 mmol/L (acute) or 4 mmol/L (chronic)

Respiratory alkalosis: For every 10mmHg↓in pCO2 below 40 mmHg, HCO3 ─ ↓ below 24.4mmol/L by
2 mmol/L (acute) or 5 mmol/L (chronic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Understand the common causes of acid base disturbances and the underlying physiological
changes that have led to the presentations and results.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Understand the role of the ABG in interpreting oxygenation problems, the causes of shift in
the O2-Haemoglobin dissociation curve and carbon monoxide poisoning.

A

If the curve is shifted to the right, this means that the bond is weaker than normal, and that oxygen more readily
dissociates from haemoglobin as it passes through the tissues, and
oxygen delivery is therefore improved. In this situation, the P50 value is > 28mmHg.

When the curve is left-shifted, the affinity of haemoglobin and oxygen is increased (stronger binding) and oxygen delivery at tissue level is therefore decreased. The P50 value is < 24mmHg. As the blood flows past the respiratory membrane the haemoglobin avidly takes up oxygen when the curve is in the leftward position.

In summary, the p50 shows us the position of the curve, and infers the quality of oxygen delivery to the tissues. Factors which shift the curve to the right do so by exerting a conformational change in the haemoglobin molecule
by binding to the globin chain. This change lessens the strength of the bond between the iron and oxygen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Understand the indications for an ABG, its limitations, its complications and the judicious use of ABG.

A

Clinical indications:
* Cardiorespiratory failure and/or Breathlessness (acute or chronic) to determine O2 or CO2.
* Metabolic disturbance eg DKA.
* Poisoning with drugs eg salicylate.
* CO poisoning (please note, cannot use haemoglobin saturation/O2 saturation probe for CO poisoning)
* Acute asthma with O2 saturation <92% (on air).
* Sepsis (lactate measurement)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Understand the difference between the ABG and VBG.

A

For patients who are not in shock, pH, Bicarbonate and base excess in VBG are close enough to arterial values to be useful.
Agreement with CO2 is not as good
Obviously, VBG does not provide useful information about O2 levels (whereas ABG does)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Be familiar with the components of spirometry and pulmonary function tests and the underlying physiology.

A

ERV Expiratory reserve volume
FRC Functional residual capacity
IC Inspiratory capacity
IRV Inspiratory reserve volume
RV Residual volume
TLC Total lung capacity
VC Vital capacity
VT Tidal volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Be able to identify patterns of obstructive, restrictive and mixed changes in PFTs.

A
  1. Normal
    Inspiratory limb of loop is symmetric and convex. Expiratory limb is linear.
  2. Restrictive disease (e.g. sarcoidosis, kyphoscoliosis)
    Configuration of loop is narrowed because of ↓lung volumes but shape is basically normal. At comparable lung volumes, flow rates are normal. (Actually ↑ because airways held open by ↑elasƟc recoil)
  3. Obstructive disease (e.g. COPD, asthma)
    All flow rates ↓, but particularly expiratory flow rate is ↓↓
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Understand the role of and be able to interpret pulmonary function testing in the diagnosis and monitoring of COPD.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Recognise the common causes of restrictive lung disease and their typical presentations.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Be able to utilise the DLCO to determine the cause of restrictive changes in pulmonary
function testing.

A

Whereas spirometry measures the mechanical properties of the lungs, the lung diffusing capacity test (DLco)
measures the ability of the lungs to perform gaseous exchange.
The ability of the lungs to pass oxygen from alveoli → pulmonary capillary blood can be affected by damage to or loss of
respiratory membrane as in emphysema, and by thickening of the membrane by fibrosis or inflammation (interstitial lung disease e.g. asbestosis)
The DLco test is more sensitive

Causes of ↓ DLco
Interstitial lung disease
Emphysema
Severe anaemia
Smoking
Late stage pulmonary oedema
Causes of ↑ DLco
Polycythaemia
Early left ventricular failure
Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Be aware of the limitations of spirometry and pulmonary function testing and demonstrate
judicious use of investigations.

A

ABSOLUTE
* Active infection
* Thoracic/ Abdominal or Cerebral
aneurysms
* Current Pneumothorax
* Recent surgery to eyes/ ears/ abdomen
or neurosurgery

RELATIVE
* Respiratory infection in the previous 4-6 weeks
* Haemoptysis of unknown origin
* Conditions aggravated by forced expiration
* Pneumothorax
* Unstable angina/ recent MI/ uncontrolled
hypertension/ Pulmonary embolism
* History of stroke/ TIA/ thoracic, abdominal or eye
surgery
* Patient is too unwell
* Communication problems/ confusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Understand the basic principles behind conventional radiography (X-ray-plain films).

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Be able to describe the advantages and disadvantages of the main imaging modalities: x-ray, ultrasound, CT and MRI.

A

X-RAY
* Radioactive beams are projected through the body and then detected by the plate
* The xray plate starts off white, as the beams hit it turns black., Denser structures (bones, metal) absorb more of the beams and therefore appear whiter. More Xrays pass through air and thus air filled lungs will appear more black.
* Chest xray projections can be Posterior/Anterior (most common), Anterior/Posterior and Lateral.
* Usage: Skeletal, Lungs, Heart
* Screening -mammograms
* Benefits: cheap, widely available, portable
* Disadvantages: radiation (but low – x 38 CXRs = b/g radiation in 1 year), 2D image

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the normal anatomy of the chest and, understand changes to this in cardiac and respiratory disease and, why these may result in abnormalities on a chest X-ray.
HEART

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe and interpret abnormalities on a chest X-ray seen in common chest conditions

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

List appropriate additional imaging investigations (other than a chest X-ray) that would bemost useful in the diagnosis and management of common presentations/conditions affecting the cardiovascular, respiratory system

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Understand the limitations and risks associated with imaging and demonstrate judicious use of imaging as a choice of investigation.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the normal anatomy and physiology of the kidney and understand the changes to
this in renal disease and, why these changes may result in abnormal renal function tests.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

List commonly used investigations (blood and urine) that assess renal function and urinary
tract pathology.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Describe the composition and characteristics of normal urine and interpret abnormal urine
test characteristics in acute kidney injury and chronic kidney disease.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Explain the use of urinary PCR, ACR and 24 hour protein collection in assessing renal
pathology and interpret abnormal urine protein test results. .

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Explain the use of first line blood tests including urea, creatinine, eGFR and electrolytes in assessing renal function and interpret common abnormalities seen in patients with renal disease.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Describe the common causes and clinical features of acute kidney injury (Pre-renal, Intrinsicrenal and Post-renal)
26
Distinguish between acute kidney injury patterns (Pre-renal, Intrinsic-renal and Post-renal) using clinical information, urine and blood tests.
27
Describe the common causes and clinical features of chronic kidney disease.
28
Explain the role of urea, creatinine, electrolytes, eGFR and urine analysis in the diagnosis and staging of chronic kidney disease.
29
Explain the pathological process of anaemia in chronic kidney disease.
30
Outline the main reasons for severe atherosclerosis in patients with CKD.
31
Identify glomerulonephritis in a patient based on typical clinical presentation and investigation results.
32
Describe the causes, clinical features and consequences of nephrotic syndrome and interpret the biochemical and urine abnormalities in this condition.
33
Explain how normal plasma and urine osmolality is maintained and interpret abnormalities in these parameters in patients with hyperosmolar hyperglycaemic syndrome, diabetes insipidus and SIADH.
34
Outline secondary tests required to determine the underlying cause of abnormal renal function.
35
Discuss the limitations of testing in patients with renal disease and demonstrate judicious use of investigations
36
Understand the role of and be able to interpret pulmonary function testing in the diagnosis and monitoring of asthma
37
Describe the normal anatomy of the chest and, understand changes to this in cardiac and respiratory disease and, why these may result in abnormalities on a chest X-ray. LUNG
38
pneumothorax
39
pulmonary hypertension
40
lung cancer
41
infection
42
pleural effusion
43
pleural effusion
44
45
46
47
TB
48
RHD
49
pericarditis
50
LVF cardiomegarly
51
LVF pulmonary edaema
52
right ventricular enlargement
53
1. What type of damage is the following LFT result consistent with? Protein (total) 73 g/L (60-80) Albumin 45 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *26* µmol/L (<20) Bilirubin (conj.) *6* µmol/L (<4) ALP *182* U/L (30-110) Gamma-GT *89* U/L (<55) ALT *472* U/L (<45) AST *580* U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Hepatocelluar
54
What type of damage is the following LFT result consistent with? Protein (total) *53* g/L (60-80) Albumin *28* g/L (35-50) Globulin 25 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *164* µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Neither
55
What type of damage is the following LFT result consistent with? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) 15 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT *82* U/L (<55) ALT *123* U/L (<45) AST *302* U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Hepatocellular damage
56
What type of damage is the following LFT result consistent with? Protein (total) 69 g/L (60-80) Albumin 38 g/L (35-50) Globulin 31 g/L (25-45) Bilirubin (total) *56* µmol/L (<20) Bilirubin (conj.) *46* µmol/L (<4) ALP *314* U/L (30-110) Gamma-GT *283* U/L (<55) ALT *61* U/L (<45) AST *47* U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Cholestasis
57
5. What type of damage is the following LFT result consistent with? Protein (total) 74 g/L (60-80) Albumin 38 g/L (35-50) Globulin 36 g/L (25-45) Bilirubin (total) 7 µmol/L (<20) Bilirubin (conj.) 2 µmol/L (<4) ALP *214* U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Neither
58
6. What type of damage is the following LFT result consistent with? Protein (total) *56* g/L (60-80) Albumin *28* g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *132* µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT *82* U/L (<55) ALT *123* U/L (<45) AST *302* U/L (<35) Hepatocellular damage (hepatitis) Cholestasis Neither
Hepatocellular
59
What type of liver disease is the following LFT most consistent with? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *47* µmol/L (<20) Bilirubin (conj.) *42* µmol/L (<4) ALP *314* U/L (30-110) Gamma-GT *283* U/L (<55) ALT 37 U/L (<45) AST 29 U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
Cholestasis
60
2. What type of liver disease is the following LFT most consistent with? Protein (total) 78 g/L (60-80) Albumin 41 g/L (35-50) Globulin 37 g/L (25-45) Bilirubin (total) 9 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 104 U/L (30-110) Gamma-GT 32 U/L (<55) ALT *61* U/L (<45) AST *84* U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
Chronic hepatitis
61
What type of liver disease is the following LFT most consistent with? Protein (total) *54* g/L (60-80) Albumin *28* g/L (35-50) Globulin 26 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *165* µmol/L (<4) ALP *917* U/L (30-110) Gamma-GT *842* U/L (<55) ALT *1564*U/L (<45) AST *1332*U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
Acute hepatitis
62
What type of liver disease is the following LFT most consistent with? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) 7 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT *82* U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
None of the above
63
What type of liver disease is the following LFT most consistent with? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) 15 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT *82* U/L (<55) ALT *123* U/L (<45) AST *302* U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
Alcohol-related liver disease
64
What type of liver disease is the following LFT most consistent with? Protein (total) 73 g/L (60-80) Albumin 45 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *26* µmol/L (<20) Bilirubin (conj.) *6* µmol/L (<4) ALP *182* U/L (30-110) Gamma-GT *89* U/L (<55) ALT *472* U/L (<45) AST *580* U/L (<35) Acute hepatitis Alcohol-related liver disease Chronic hepatitis Cholestasis None of the above
acute hepatitis
65
What is the most likely cause of the following LFT result? Protein (total) *56* g/L (60-80) Albumin *28* g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *132* µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT *82* U/L (<55) ALT *123* U/L (<45) AST *302* U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
Cirrhosis
66
2. What is the most likely cause of the following LFT result? Protein (total) 69 g/L (60-80) Albumin 38 g/L (35-50) Globulin 31 g/L (25-45) Bilirubin (total) *56* µmol/L (<20) Bilirubin (conj.) *46* µmol/L (<4) ALP *314* U/L (30-110) Gamma-GT *283* U/L (<55) ALT *61* U/L (<45) AST *47* U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
Cholestasis
67
What is the most likely cause of the following LFT result? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *92* µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
Gilberts- none of the above
68
What is the most likely cause of the following LFT result? Protein (total) 78 g/L (60-80) Albumin 41 g/L (35-50) Globulin 37 g/L (25-45) Bilirubin (total) 9 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 104 U/L (30-110) Gamma-GT 32 U/L (<55) ALT *61* U/L (<45) AST *84* U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
Chronic hepatitis
69
5. What is the most likely cause of the following LFT result? Protein (total) *54* g/L (60-80) Albumin *28* g/L (35-50) Globulin 26 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *165* µmol/L (<4) ALP *917* U/L (30-110) Gamma-GT *842* U/L (<55) ALT *1564*U/L (<45) AST *1332*U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
acute liver injury/failure
70
What is the most likely cause of the following LFT result? Protein (total) *56* g/L (60-80) Albumin *28* g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *219* µmol/L (<20) Bilirubin (conj.) *132* µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
cirrhosis
71
What is the most likely cause of the following LFT result? Protein (total) 73 g/L (60-80) Albumin 45 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *26* µmol/L (<20) Bilirubin (conj.) *6* µmol/L (<4) ALP *182* U/L (30-110) Gamma-GT *89* U/L (<55) ALT *472* U/L (<45) AST *580* U/L (<35) Acute hepatitis Acute liver injury/failure Chronic hepatitis Cirrhosis Cholestasis None of the above
acute liver injury/failure
72
What is the most likely cause of the following LFT result? Protein (total) 74 g/L (60-80) Albumin 38 g/L (35-50) Globulin 36 g/L (25-45) Bilirubin (total) 7 µmol/L (<20) Bilirubin (conj.) 2 µmol/L (<4) ALP *214* U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Cholestasis Haemolytic anaemia Hepatitis Malnutrition Paget’s disease
Pagets disease
73
What is the most likely cause of the following LFT result? Protein (total) 78 g/L (60-80) Albumin 41 g/L (35-50) Globulin 37 g/L (25-45) Bilirubin (total) 9 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 104 U/L (30-110) Gamma-GT 32 U/L (<55) ALT *61* U/L (<45) AST *84* U/L (<35) Cholestasis Haemolytic anaemia Hepatitis Malnutrition Paget’s disease
Hepatitis
74
What is the most likely cause of the following LFT result? Protein (total) *50* g/L (60-80) Albumin *28* g/L (35-50) Globulin *22* g/L (25-45) Bilirubin (total) 7 µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Cholestasis Haemolytic anaemia Hepatitis Malnutrition Paget’s disease
Malnutrition
75
What is the most likely cause of the following LFT result? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *92* µmol/L (<20) Bilirubin (conj.) 3 µmol/L (<4) ALP 62 U/L (30-110) Gamma-GT 42 U/L (<55) ALT 34 U/L (<45) AST 32 U/L (<35) Cholestasis Haemolytic anaemia Hepatitis Malnutrition Paget’s disease
haemolytic anaemia
76
What is the most likely cause of the following LFT result? Protein (total) 66 g/L (60-80) Albumin 38 g/L (35-50) Globulin 28 g/L (25-45) Bilirubin (total) *47* µmol/L (<20) Bilirubin (conj.) *42* µmol/L (<4) ALP *314* U/L (30-110) Gamma-GT *283* U/L (<55) ALT 37 U/L (<45) AST 29 U/L (<35) Cholestasis Haemolytic anaemia Hepatitis Malnutrition Paget’s disease
cholestatisis
77
An ovarian mass is seen on pelvic USS. What finding/characteristic would suggest an ovarian cancer over other causes? Multilocated mass Multiple anechoic lesions Multiple echogenicities with little anechoic areas Fluid in pouch of Douglas
Multiple echogenicities with little anechoic areas
78
An USS of the pelvis shows a uniformly thickened, regular endometrium of 18mm. What is the most likely cause/diagnosis? Endometriosis Endometrial polyp Endometrial hyperplasia Endometrial cancer Pregnancy
Endometrial hyperplasia